Clinical Trial Seeking Patients for the Study of an Investigational Medication For the Treatment of Irritable Bowel Syndrome

Apr 03, 2001, 01:00 ET from GI Research

    LAKE FOREST, Ill, April 3 /PRNewswire/ -- Male and female volunteers are
 needed to participate in a research study for people who suffer from symptoms
 of Irritable Bowel Syndrome (IBS).  This placebo-controlled research study,
 currently being conducted by TAP Pharmaceutical Products Inc., will evaluate
 the safety and effectiveness of an investigational medication for the
 treatment of Irritable Bowel Syndrome.
     IBS is a common gastrointestinal disorder that causes abdominal pain,
 bloating, gas, diarrhea, constipation or a combination of these symptoms. IBS
 is the most common gastrointestinal diagnosis among gastroenterology practices
 in the U.S., and is one of the top ten most frequently diagnosed conditions
 among U.S. physicians.
     IBS affects an estimated one in five adult Americans.  Three times more
 women suffer from IBS than men, making it more common than other chronic
 conditions affecting women such as osteoporosis, arthritis, and diabetes.
 Typically symptoms of IBS begin in early adult life through age 40, when the
 pressures of college and raising families increase physical and emotional
 stress.
     Male and female volunteers are currently being screened for participation
 in this important clinical trial being conducted nationwide.  Qualified
 participants will receive study-related medication and study-related health
 assessments.  Potential study volunteers should call 1-888-STUDY-98
 (1-888-788-3998), extension 123, for additional information.
     TAP Pharmaceutical Products Inc., located in Lake Forest, IL, is a joint
 venture between Abbott Laboratories, headquartered in Abbott Park, IL, and
 Takeda Chemical Industries, Ltd. Of Osaka, Japan.
 
 

SOURCE GI Research
    LAKE FOREST, Ill, April 3 /PRNewswire/ -- Male and female volunteers are
 needed to participate in a research study for people who suffer from symptoms
 of Irritable Bowel Syndrome (IBS).  This placebo-controlled research study,
 currently being conducted by TAP Pharmaceutical Products Inc., will evaluate
 the safety and effectiveness of an investigational medication for the
 treatment of Irritable Bowel Syndrome.
     IBS is a common gastrointestinal disorder that causes abdominal pain,
 bloating, gas, diarrhea, constipation or a combination of these symptoms. IBS
 is the most common gastrointestinal diagnosis among gastroenterology practices
 in the U.S., and is one of the top ten most frequently diagnosed conditions
 among U.S. physicians.
     IBS affects an estimated one in five adult Americans.  Three times more
 women suffer from IBS than men, making it more common than other chronic
 conditions affecting women such as osteoporosis, arthritis, and diabetes.
 Typically symptoms of IBS begin in early adult life through age 40, when the
 pressures of college and raising families increase physical and emotional
 stress.
     Male and female volunteers are currently being screened for participation
 in this important clinical trial being conducted nationwide.  Qualified
 participants will receive study-related medication and study-related health
 assessments.  Potential study volunteers should call 1-888-STUDY-98
 (1-888-788-3998), extension 123, for additional information.
     TAP Pharmaceutical Products Inc., located in Lake Forest, IL, is a joint
 venture between Abbott Laboratories, headquartered in Abbott Park, IL, and
 Takeda Chemical Industries, Ltd. Of Osaka, Japan.
 
 SOURCE  GI Research